A review of data systems for assessing the impact of HPV vaccination in selected high-income countries

References

• Lacey CJ, Lowndes CM, Shah KV. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24:S35–S41.
   Web of Science ®Google Scholar
• Bruni L, Albero G, Serrano B, et al. ICO/IARC information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in the world. Summary report. 2019;22.
   Google Scholar
• CDC A. How many cancers are linked with HPV each year? 2018.
   Google Scholar
• de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203.
   PubMed Web of Science ®Google Scholar
• Global Cancer Observatory. Cancer Today - Estimated number of new cases in 2020, worldwide, females, all ages (excl. NMSC). https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1 (accessed Nov 2022.
   Google Scholar
• Hall MT, Simms KT, Lew J-B, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4(1):e19–e27.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer. https://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en/ (accessed Nov 2022, 2019).
   Google Scholar
• World Health Organization. Cervical Cancer Elimination Initiative. https://www.who.int/initiatives/cervical-cancer-elimination-initiative (accessed Nov 2022.
   Google Scholar
• European Medicines Agency. Cervarix: human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed). https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix (accessed Nov 2022.
   Google Scholar
• World Health Organization. Cecolin: human Papillomavirus (Bivalent). https://extranet.who.int/pqweb/content/cecolin%C2%AE (accessed Nov 2022.
   Google Scholar
• European Medicines Agency. Gardasil: human papillomavirus vaccine [ types 6, 11, 16, 18] ( recombinant, adsorbed). https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil (accessed Nov 2022.
   Google Scholar
• GAVI.com. Millions to benefit from Indian-made cervical cancer vaccine. HPV vaccination in south Asia: new progress, old challenges [editorial]. The Lancet Oncology. 2022;23(10):1233. https://www.gavi.org/vaccineswork/millions-benefit-indian-made-affordable-cervical-cancer-vaccine
   Google Scholar
• European Medicines Agency. Gardasil 9: human papillomavirus 9-valent vaccine (recombinant, adsorbed). https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil-9 (accessed Nov 2022.
   Google Scholar
• de Sanjose S, Brotons M, LaMontagne DS, et al. Human papillomavirus vaccine disease impact beyond expectations. Curr Opin Virol. 2019;39:16–22.
   PubMed Web of Science ®Google Scholar
• Arie S. HPV: WHO calls for countries to suspend vaccination of boys. BMJ. 2019;367:l6765. DOI:10.1136/bmj.l6765
   PubMedGoogle Scholar
• Garland SM. The Australian experience with the human papillomavirus vaccine. Clin Ther. 2014;36(1):17–23.
   PubMed Web of Science ®Google Scholar
• White MD. Pros, cons, and ethics of HPV vaccine in teens—Why such controversy? Transl Androl Urol. 2014;3(4):429.
   PubMedGoogle Scholar
• PATH. Global HPV Vaccine Introduction Overview. https://path.azureedge.net/media/documents/Global_HPV_Vaccine_Intro_Overview_Slides_webversion_2020May.pdf (accessed Nov 2022.
   Google Scholar
• MSD data on file
   Google Scholar
• Chido-Amajuoyi OG, Talluri R, Wonodi C, et al. Trends in HPV Vaccination Initiation and Completion Within Ages 9–12 Years: 2008–2018. Pediatrics. 2021;147(6). DOI:10.1542/peds.2020-012765
   PubMed Web of Science ®Google Scholar
• Chow EP, Carter A, Vickers T, et al. Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004–18. Lancet Infect Dis. 2021;21(12):1747–1756.
   PubMed Web of Science ®Google Scholar
• Franco M, Mazzucca S, Padek M, et al. Going beyond the individual: how state-level characteristics relate to HPV vaccine rates in the United States. BMC Public Health. 2019;19(1):1–9.
   PubMedGoogle Scholar
• Tjalma W, Brasseur C, Top G, et al. HPV vaccination coverage in the federal state of Belgium according to regions and their impact. Facts Views Vis Obgyn. 2018;10(2):101.
   PubMed Web of Science ®Google Scholar
• Wong CA, Saraiya M, Hariri S, et al. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. Vaccine. 2011;29(5):878–885.
   PubMed Web of Science ®Google Scholar
• Organization WH. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241–268.
   PubMedGoogle Scholar
• Garland SM, Brotherton JM, Condon JR, et al. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med. 2011;9(1):104.
   PubMedGoogle Scholar
• Machalek DA, Garland SM, Brotherton JM, et al. Very low prevalence of vaccine human papillomavirus types among 18-to 35-year old Australian women 9 years following implementation of vaccination. J Infect Dis. 2018;217(10):1590–1600.
   PubMed Web of Science ®Google Scholar
• Brotherton J, Kaldor J, Garland S. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sex Health. 2010 Sep;7(3):310–319.
   PubMed Web of Science ®Google Scholar
• Brotherton JM. Impact of HPV vaccination: achievements and future challenges. Papillomavirus Res. 2019;7:138.
   PubMed Web of Science ®Google Scholar
• World Bank. World Bank list of economies. https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html (accessed Nov 2022, 2019).
   Google Scholar
• Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Rev Infect Dis. 2016;63(4):519–527.
   Google Scholar
• Fonteneau L, Ragot M, Guthmann J, et al. Use of health care reimbursement data to estimate vaccination coverage in France: example of hepatitis B, meningitis C, and human papillomavirus vaccination. Rev Epidemiol Sante Publique. 2015;63(5):293–298.
   PubMed Web of Science ®Google Scholar
• Leval A, Herweijer E, a P, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst. 2013;105(7):469–474.
   PubMedGoogle Scholar
• Australian Institute of Health and Welfare. How are causes of death coded? On Australian Institute of Health and Welfare. https://www.aihw.gov.au/about-our-data/our-data-collections/national-mortality-database/how-are-causes-of-death-coded. (accessed Nov 2022.
   Google Scholar
• Health Information Quality Authority. CervicalCheck (National Cervical Screening Register). https://www.hiqa.ie/areas-we-work/health-information/data-collections/cervicalcheck-national-cervical-screening. (accessed Nov 2022.
   Google Scholar
• Minardi V, Campostrini S, Carrozzi G, et al. Social determinants effects from the Italian risk factor surveillance system PASSI. Int J Public Health. 2011;56(4):359–366.
   PubMed Web of Science ®Google Scholar
• Kvalitetsregister N, National quality registry for cervical cancer prevention, On Nationella Kvalitetsregister website, updated 2019 Sep 12; cited 2019 Oct 17. [Online]. Available: http://kvalitetsregister.se/englishpages/findaregistry/registerarkivenglish/nationalqualityregistryforcervicalcancerprevention.2152.html.
   Google Scholar
• Heard I, Tondeur L, Arowas L, et al. Distribution des papillomavirus humains (HPV) dans des frottis effectués dans le cadre du dépistage organisé du cancer du col de l’utérus en France. Bulletin Epidémiologique Hebdomadaire. 2014;(241):248.
   Google Scholar
• Maura G, Chaignot C, Weill A, et al. Cervical cancer screening and subsequent procedures in women under the age of 25 years between 2007 and 2013 in France: a nationwide French healthcare database study. Eur J Cancer Prev. 2018;27(5):479–485.
   PubMed Web of Science ®Google Scholar
• Institut National du Cancer. Le programme national de dépistage du cancer du col de l’utérus. https://www.e-cancer.fr/Comprendre-prevenir-depister/Se-faire-depister/Depistage-du-cancer-du-col-de-l-uterus/Le-programme-national-de-depistage (accessed Nov 2022.
   Google Scholar
• Centre for Health Record Linkage. NSW pap test register data dictionary for record linkage. NSW cervical screening program. On Centre for Health Record Linkage website. http://www.cherel.org.au/data-dictionaries. (accessed Nov 2022, 2020).
   Google Scholar
• Garland SM, Dimech W, Collignon P, et al. The new screening program to prevent cervical cancer using HPV DNA: getting the balance right in maintaining quality. The Journal of Pathology: Clinical Research. 2018;4(4):207–212.
   PubMedGoogle Scholar
• Heard GA, Fihman I, Duport V, et al. Caractéristiques de l’infection par les papillomavirus humains dans des frottis cervicaux normaux en France en 2009. Bulletin Epidémiologique Hebdomadaire. 2011;314–316
   Google Scholar
• Garland SM, Brotherton JM, Condon JR, et al. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program, (in eng. BMC Med. 2011 Sep 13;9(1):104.
   PubMedGoogle Scholar
• Australian Government Department of Health. Human Papillomavirus (HPV). https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-HPV.htm (accessed Nov 2022.
   Google Scholar
• The Kirby Institute. Genital Warts Surveillance Network Report 2004 – 2015. https://kirby.unsw.edu.au/report/genital-warts-surveillance-network-report-2004-2015 (accessed Nov 2022.
   Google Scholar
• Campisi P, Hawkes M, Simpson K. The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database. Laryngoscope. 2010 Jun;120(6):1233–1245.
   PubMed Web of Science ®Google Scholar
• Deverell M, Zurynski YA, Elliott EJ. Australian Paediatric Surveillance Unit annual report, 2013. Commun Dis Intell Q Rep. 2014;38(4):E343–2.
   PubMedGoogle Scholar
• Novakovic D CA, Zurynski Y, Booy R, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis. 2018;217(2):208–212.
   PubMed Web of Science ®Google Scholar
• Carvalho CM, Huot L, Charlois AL, et al. Prognostic factors of recurrent respiratory papillomatosis from a registry of 72 patients. Acta Otolaryngol. 2009;129(4):462–470.
   PubMed Web of Science ®Google Scholar
• Reeves WC, Ruparelia SS, Swanson KI, et al. National registry for juvenile-onset recurrent respiratory papillomatosis, (in eng. Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):976–982.
   PubMedGoogle Scholar
• Novakovic D, Cheng AT, Baguley K, et al. Juvenile recurrent respiratory papillomatosis: 10-year audit and Australian prevalence estimates, (in eng. Laryngoscope. 2016 Dec;126(12):2827–2832.
   PubMed Web of Science ®Google Scholar
• Taylor R, Bell J, Coates M, et al. Cervical cancer in New South Wales women: five-year survival, 1972 to 1991. Aust N Z J Public Health. 1996;20(4):413–420.
   PubMed Web of Science ®Google Scholar
• Everhov AH, Nyberg T, Bergmark K, et al. Hormone therapy after uterine cervical cancer treatment: a Swedish population-based study. Menopause. 2015;22(6):633–639.
   PubMed Web of Science ®Google Scholar
• Edgren G, Sparen P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 2007;8(4):311–316.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Market Study - HPV. https://cdn.who.int/media/docs/default-source/immunization/mi4a/who-hpv-vaccine-global-market-study-april-2022.pdf?sfvrsn=6acb4c98_1&download=true (accessed Nov 2022.
   Google Scholar
• Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018;36(32):4761–4767.
   PubMed Web of Science ®Google Scholar